Our Company

OverviewManagement TeamBoard of DirectorsScientific Advisory BoardPartners & Collaborations

Zentalis develops small molecule therapeutics with differentiated product profiles for a broad range of cancers.

Utilizing our Integrated Discovery Engine, the Company is developing a focused pipeline of potentially best-in-class oncology candidates, which include azenosertib, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in both New York and San Diego.

Management Team

Kimberly Blackwell, MD

Chief Executive Officer and Director

Cam Gallagher, MBA

Cofounder, President and Director, Interim CFO

Kimberly Freeman

Chief Strategy Officer

Diana Hausman, MD

Chief Medical Officer

Mark Lackner, PhD

Chief Scientific Officer

Andrea Paul, JD

Chief Legal Officer and Corporate Secretary

Kyle Rasbach, PhD, PharmD

Chief Business Officer

Board of Directors

Dave Johnson


Kimberly Blackwell, MD

Chief Executive Officer

Cam Gallagher, MBA

Cofounder, President and Director

Enoch Kariuki, PharmD


Jan Skvarka, PhD, MBA


Karan Takhar


Luke Walker, M.D.


Scientific Advisory Board

Anthony Letai, MD, PhD

Harvard Medical School

Ross Levine, MD

Memorial Sloan Kettering Cancer Center

Funda Meric-Bernstam, MD

MD Anderson Cancer Center

Adam Schayowitz, PhD, MBA


Kwok-Kin Wong, MD, PhD

NYU Langone Health

Partners & Collaborators

Please contact us at bd@zentalis.com to discuss partnering and collaboration opportunities.